> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vir Flu Vaccine Fails Phase 2 Trial
- URL: https://www.fdaweb.com/vir-flu-vaccine-fails-phase-2-trial/
- Published: 2023-07-20T12:00:00.000Z
- Updated: 2026-09-14T18:45:32.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5154916

Vir Biotechnology says its VIR-2482 failed to meet primary and secondary endpoints in the Phase 2 PENINSULA trial to prevent symptomatic influenza A illness. A company statement says VIR-2482 was generally well tolerated and no safety signals were identified.

VIR-2482 is described as an investigational hemagglutinin intramuscularly administered influenza A-neutralizing monoclonal antibody. Vir says it is designed as a prophylactic for influenza A and that it has the potential to address the limitations of current flu vaccines due to its broad strain coverage and because it does not rely on an individual to create their own protective antibody response.